PHOTOCURE ANNOUNCES THE ACHIEVEMENT OF THE FIRST TRANSITION MILESTONE OF EUR
2.0 MILLION FOR HEXVIX(®)

Oslo, Norway, October 11, 2011: Photocure ASA (OSE: PHO), a specialty
pharmaceutical company focused on photodynamic technologies in dermatology and
cancer, announces today the achievement of the first transition milestone from
Ipsen, its new strategic partner for commercialising Hexvix worldwide, excluding
the US and Nordic region.

On September 27, Photocure and Ipsen announced a new strategic collaboration for
the commercialization of Hexvix. In accordance with the agreement with Ipsen,
Photocure will receive a total of EUR 5 million in transition payments.
Photocure has successfully completed the first transition milestone which
triggered a EUR 2.0 million payment. This milestone is in addition to the EUR
1.5 million that was received upon signing of the agreement.

Photocure will receive an additional EUR 3 million upon achievements of
remaining transition milestones, estimated to be completed by first quarter
2012. Additionally Photocure will receive double digit royalties on all sales,
milestones on specific sales achievements and will manufacture the product for
Ipsen.

In the new partnership, Ipsen will be responsible for marketing and selling
Hexvix worldwide, excluding the US and Nordic region. Ipsen has a strong and
well established uro-oncology franchise and will commercialize Hexvix through
its dedicated urology salesforce.

Kjetil Hestdal, President & CEO of Photocure, said:
"We are happy to see that the transition is going according to our plans and
that we are delivering on our commitments to Ipsen to secure an optimal
transition for Hexvix".

For further information, please contact:

Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:kh@photocure.no

CFO Christian Fekete
Tel: + 47 916 42 938, Email:cf@photocure.no

M: Communications

Mary Clark, Amber Bielecka

Tel: +44 207920 2361, Email: photocure@mcomgroup.com

About Hexvix

Hexvix/Cysview (hexaminolevulinate hydrochloride for intravesical solution), is
the first approved drug-device procedure for improved detection of bladder
cancer. It is designed to induce fluorescence in the malignant cells in the
bladder during a cystoscopic procedure, making it easier for the urologist to
detect non muscle invasive bladder cancer, as an adjunct to white light
cystoscopy. Clinical data show an up to 30% increase in detection of the
malignant cells in the bladder as compared to the white light system, bringing
the total detection rate to 96%. Hexvix also showed a 32% increase in detection
of carcinomas in situ, where tumor cells have not yet penetrated in deep
tissues, but carry high risk of progression. It is the first product in a new
diagnostic class known as photodynamic diagnostic (PDD) agents.

The product is used in combination with a blue light cystoscopy system. Blue
light cystoscopes are broadly available across Europe, where there are an
estimated 800 systems currently placed. In the US there are currently only a few
systems available. Karl Storz has submitted a supplement to the approved PMA to
the FDA for an improved blue light system. This system is similar to the model
sold in Europe. Karl Storz estimates that FDA will respond to this application
in the fourth quarter 2011.

In November 2010, clinical results from a follow up of recurrence in patients
with Non Muscle Invasive Bladder Cancer were published. Results, based on both
EU and US clinical data, showed a long term benefit of the use of Hexvix
compared to patients who received white light cystoscopy alone. The number of
patients who have experienced recurrence of their bladder cancer is
significantly lower, and the time it takes before the recurrence occurs is
longer when they had Hexvix-guided fluorescence cystoscopy, although this has
not yet been approved by the relevant regulatory authorities.

Bladder cancer is the fourth most common type of cancer in men and the eighth
most common in women in the US. More than 70,000 people in the US were diagnosed
with cancer of the bladder in 2009, with an estimated 14,000 people dying from
the disease, according to the National Cancer Institute. In Europe, bladder
cancer is the seventh most common type of cancer in men and the fourteenth in
women. Each year in Europe, approximately 36,500 men and 13,000 women die due
bladder cancer (Ferlay et al., 2001).It is notoriously difficult to detect. The
most common, initial sign is red-colored urine, which calls for urine cytology
and cystoscopy.

About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic technology. Listed on the
Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic
technologies in dermatology and cancer. The company strives to solve unmet needs
by developing new and innovative solutions based on its patented Photocure
Technology(TM). Photocure markets and sells its own products in selected markets
and has developed strong partnerships with leading pharmaceutical companies on a
regional and global basis. Photocure's bladder cancer diagnostic product, Hexvix
is approved in Europe and the US. In addition, the company markets Allumera®, a
photodynamic cosmetic in the US. Setting new standards for diagnosis and
treatment of several different conditions, Photocure Technology(TM) is
continuously being tested for new products and applications in cancer and
dermatology.
Allumera®, Photocure® and Hexvix® are registered trademarks of Photocure ASA.
For more information about Photocure, visitwww.photocure.com.

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)

[HUG#1553820]

Photocure ASA - First transition milestone from Ipsen